OrbiMed Advisors CALC Position
ExitedOrbiMed Advisors exited their position in CalciMedica, Inc. (CALC) in Q2 2024, after holding the stock for 5 quarters.
The position was first reported in Q2 2023 and has been tracked across 5 quarterly 13F filings.
1 other tracked fund also holds CALC.
There is an upcoming Phase 2 readout for Auxora in 14 days (Apr 30, 2026), making the timing of OrbiMed's position particularly relevant.
About CalciMedica, Inc.
CalciMedica, Inc., a clinical-stage biotechnology company, focuses on developing therapies for life-threatening inflammatory diseases with unmet needs. Its proprietary technology targets the inhibition of calcium release-activated (CRAC) channels designs to modulate the immune response and protect against tissue cell injury in life-threatening inflammatory diseases. Its lead product candidate is Auxora, a proprietary intravenous-formulated CRAC channel inhibitor for the treatment of acute pancreatitis, asparaginase-associated acute pancreatitis, and acute kidney injury. The company is based in La Jolla, California.
Full company profile →Short Interest
4.1%
0.9 days to cover
OrbiMed Advisors CALC Position History
Frequently Asked Questions
Does OrbiMed Advisors own CALC?
No. OrbiMed Advisors exited their position in CalciMedica, Inc. (CALC) in Q2 2024. They previously held the stock for 5 quarters.
How many hedge funds own CALC?
1 specialist biotech hedge fund currently holds CALC, including Deerfield Management. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did OrbiMed Advisors first buy CALC?
OrbiMed Advisors's position in CALC was first reported in Q2 2023. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is OrbiMed Advisors's CALC position increasing or decreasing?
OrbiMed Advisors completely exited their CALC position in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
CALCCompany Page →
All fund holders, insider trades, catalysts, and cash runway
OrbiMed AdvisorsPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →